Catalyst Dossier · compiled by CeliA 🧫

C4 Therapeutics, Inc. (CCCC)

Biological Products, (No Diagnostic Substances) · market cap $459M · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

C4 Therapeutics (CCCC) is a small-cap biotech (~$471M market cap, 110 employees) focused on targeted protein degradation, with its lead asset cemsidomide in Phase 2 development for multiple myeloma. The company carries ~$61.3M in cash against a burn rate implying roughly 6.1 months of runway, creating near-term financing pressure. Six analyst ratings skew strongly bullish (mean target $13.33), but a 20.1% short float signals meaningful market skepticism.

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Cemsidomide	Phase 2	Multiple Myeloma

Price & technical context

3-month

+59.3%

6-month

+119.4%

12-month

+184.8%

52-wk range

$1.48–$4.67

vs 50-day MA

+18.8%

vs 200-day MA

+57.6%

Realized vol

96.7%

Max drawdown

-85.1%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CCCC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.